Targets › GUCY1B1
15 programs from 14 companies in 29 trials: 13 Phase 2, 7 Phase 4, 6 Phase 3, 3 Phase 1; Cardiovascular, Oncology, Genitourinary; next expected readout Dec 2026.
Beta subunit of soluble guanylate cyclase (sGC), a key enzyme in nitric oxide (NO) signaling. sGC functions as a heterodimer consisting of one alpha and one beta subunit. It serves as the primary intracellular receptor for NO, which binds to a heme prosthetic group located on the beta subunit. (UniProt, Q02153)
Open in Phaseline: the race on GUCY1B1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Copenhagen University Hospital, Rigshospitalet | Isosorbide Dinitrate Nitrate; nitric oxide donor causing vasodilation | GUCY1A1, GUCY1B1 | Phase 4 | Pulmonary Edema | May 2027 |
| National Cheng-Kung University Hospital | Nitroglycerin Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 4 | Pancreatitis | Jul 2027 |
| Pulmovant | inhaled mosliciguat soluble guanylate cyclase stimulator | GUCY1A1, GUCY1B1 | Phase 3 | Pulmonary Hypertension | Dec 2026 |
| Children's Hospital Medical Center, Cincinnati | Nitric Oxide Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | AKI | Jun 2027 |
| Xijing Hospital | Nitric Oxide Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | Nitric Oxide | Mar 2028 |
| Bayer | Riociguat Soluble guanylate cyclase positive allosteric modulator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | Hypertension, Pulmonary; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial Hypertension | May 2028 |
| Akebia Therapeutics | Praliciguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Focal Segmental Glomerulosclerosis | Jun 2027 |
| Coherus Oncology | Casdozokitug Soluble guanylate cyclase stimulator | GUCY1A1, GUCY1B1 | Phase 2 | Hepatocellular Carcinoma | Sep 2027 |
| Kardigan | Ataciguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Moderate Aortic Valve Stenosis | Aug 2028 |
| Merck & Co. (MSD) | Vericiguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF); Endothelial Dysfunction; Post-COVID ME/CFS … | Aug 2029 |
| Merck & Co. (MSD) | Frespaciguat (MK-5475) Soluble guanylate cyclase (sGC) stimulator | GUCY1A1, GUCY1B1 | Phase 2 | Pulmonary Hypertension | Oct 2029 |
| Steven Messe | Nitric Oxide Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Stroke | – |
| Beni-Suef University | Nitroglycerin Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | COPD | – |
| Mayo Clinic | Isosorbide Mononitrate Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 1 | Malignant Digestive System Neoplasm | Apr 2028 |
| Vanderbilt University | Nitroglycerin Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 1 | Hypertension | Jul 2028 |
Pulmonary Hypertension (4) Heart Failure (3) Chronic Thromboembolic Pulmonary Hypertension (2) Pulmonary Arterial Hypertension (2) Nitric Oxide (1) COPD (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1) Endothelial Dysfunction (1) Post-COVID ME/CFS (1) Breast Cancer (1) Calcific Aortic Valve Disease (1) Decompensated Heart Failure (1)
small molecule (14), antibody (1)
Merck & Co. (MSD) (2) Pulmovant (1) Xijing Hospital (1) Beni-Suef University (1) National Cheng-Kung University Hospital (1) Children's Hospital Medical Center, Cincinnati (1) Kardigan (1) Coherus Oncology (1) Bayer (1) Akebia Therapeutics (1) Vanderbilt University (1) Mayo Clinic (1) Steven Messe (1) Copenhagen University Hospital, Rigshospitalet (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.